A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
Status:
Terminated
Trial end date:
2018-08-23
Target enrollment:
Participant gender:
Summary
This is a first-time-in-human, phase I, open-label, dose-escalation study of HMPL-453 in
patients with advanced or metastatic solid malignancies who have failed or are intolerable to
standard therapies or for whom no standard therapies exist. There are preliminary two stages
in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). We
will decide whether to conduct stage 2 or not one month after the last patient included in
stage 1.